Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
AUPH Stock Chart & Stats
$15.79
$0.10(1.19%)
At close: 4:00 PM EST
$15.79
$0.10(1.19%)
Day’s Range― - ―
52-Week Range$6.55 - $16.48
Previous CloseN/A
Volume460.34K
Average Volume (3M)1.85M
Market Cap
$2.09B
Enterprise Value$1.23B
Total Cash (Recent Filing)$351.81M
Total Debt (Recent Filing)$78.21M
Price to Earnings (P/E)28.1
Beta0.46
Next Earnings
Mar 04, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding131,840,560
10 Day Avg. Volume1,479,528
30 Day Avg. Volume1,850,061
Financial Highlights & Ratios
PEG Ratio-2.08
Price to Book (P/B)3.40
Price to Sales (P/S)5.46
P/FCF Ratio29.13
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda12.00
Forecast
1Y Price Target
$16.50Price Target Upside4.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.78
Revenue Forecast (FY)$279.14M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported a net income per diluted share that exceeded the consensus estimate, indicating strong financial performance.
Guidance IncreaseThe company raised its 2025 total revenue guidance, reflecting confidence in continued positive impact from updated guidelines and increased Lupkynis adoption.
Revenue GrowthProduct sales grew 27% year-over-year on continued momentum from high volume prescribers.
Bears Say
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $6.55 and its highest was $16.48 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $2.09B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 75 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.22.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 131,840,560 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.23 in its last earnings report, beating expectations of $0.16. Following the earnings report the stock price went up 8.352%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.50 (4.50% Upside)
$16.50 (4.50% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 25.7%
Last 30 Days ▲ 25.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.58%
12-Months-Change
Fundamentals
Return on Equity
20.65%
Trailing 12-Months
Asset Growth
-3.97%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune and kidney diseases. The company's primary product, LUPKYNIS (voclosporin), is an FDA-approved treatment for lupus nephritis, a serious and potentially life-threatening condition. Aurinia is committed to advancing medical science by conducting rigorous clinical trials and engaging with healthcare professionals to improve patient outcomes in underserved areas of medicine.
AUPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showed strong sales growth and financial performance, particularly for LUPKYNIS, alongside promising clinical developments with aritinercept. However, regulatory and legal issues present potential challenges.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$16.50
▲(4.50% Upside)
Technical Analysis
Ownership Overview
11.42% Insiders
4.69% Mutual Funds
17.09% Other Institutional Investors
59.85% Public Companies and Individual Investors